Guggenheim Assumes Nanobiotix at Buy, Announces Price Target of $64

Benzinga Newsdesk www.benzinga.com Neutral 74.6%

Neg 0% Neu 74.6% Pos 0%

Guggenheim analyst Paul Jeng assumes Nanobiotix (NASDAQ:NBTX) with a Buy rating and announces Price Target of $64.

Comments

No comments yet. Be the first!